Journal: Molecular Oncology
Article Title: Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD‐L1 ‐expressing head and neck cancer
doi: 10.1002/1878-0261.13633
Figure Lengend Snippet: Anti‐PD‐L1 treatment elicits increased intramucosal T‐cell infiltration and decreased blood vascular density with proper pericyte coverage. Mice were submucosally injected with 5 × 10 5 AOC3‐LN cells in the left buccal area and intraperitoneally injected with an anti‐PD‐L1 inhibitor (10 mg·kg −1 ) twice a week for 3 weeks. (A–D) Immunofluorescence images showing CD8: representing T‐cells, CD31: representing blood vessels, NG2: representing pericyte coverages, and GLUT1: representing hypoxic condition expression level in the tumor microenvironment. Scale bars, 100 μm. (E–H) Comparisons of CD8: representing T‐cells, CD31: representing blood vessels, NG2: representing pericyte coverages, and GLUT1: representing hypoxic condition expression level between control and anti‐PD‐1‐treated groups; Values are expressed as means ± SD, n = 6 in Control, n = 6 in PD‐L1; Student's T tests were performed between groups and * P < 0.05 versus control. (I) Intratumor VEGF levels were assessed using an ELISA kit; Values are expressed as means ± SD, n = 6 in Control, n = 6 in PD‐L1; Student's T tests were performed between groups and * P < 0.05 versus control. Representative results obtained from three repetitive experiments with the same number of mice. ELISA, enzyme‐linked immunosorbent assay; LN, lymph node; PD, programmed death; VEGF, vascular endothelial growth factor receptor.
Article Snippet: Subsequently, the tissue sections were blocked with 5% goat serum in PBST (0.1% Triton X‐100 in PBS) and incubated for 3 h at room temperature with the following primary antibodies: hamster anti‐CD31 (clone 2H8; Millipore, Burlington, MA, USA), rabbit anti‐PD‐L1 (clone 28‐8; BD Biosciences, San Jose, CA, USA), hamster anti‐CD3e (clone 145‐2C11; BD Biosciences), rat anti‐CD8 (clone 53‐6.7; BD Biosciences), rat anti‐CD4 (clone RM4‐5; eBioscience, San Diego, CA, USA), rat anti‐F4/80 (clone BM8; eBioscience), rat anti‐Ly6G (clone 1A8; BD Biosciences), rat anti‐NG2 (clone 546 930; Invitrogen, Carlsbad, CA, USA), rabbit anti‐GLUT1 (clone SA0377; Invitrogen).
Techniques: Injection, Immunofluorescence, Expressing, Control, Enzyme-linked Immunosorbent Assay
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
